Biogen Tangoes its way into Alzheimer’s, again

Snippets

The failure of Biogen’s anti-tau antibody BIIB092 in progressive supranuclear palsy (PSP) has not stopped Biogen from continuing its pursuit of Alzheimer's disease: development of BIIB092, also known as gosuranemab, will continue in the phase II Tango trial in patients with mild cognitive impairment. The PSP setback, however, might not have been a huge surprise given Abbvie’s earlier ABBV-8E12 failure in the same indication using an anti-tau antibody. In Alzheimer’s the tau hypothesis is proving to be just as controversial as amyloid beta, and according to Stifel analysts it is still an open question whether antibodies can clear tau from the brain, as the protein largely accumulates inside neurons. Nevertheless, big pharma continues to chase this elusive holy grail with Lilly, Roche, Abbvie and Eisai all having anti-tau MAbs in early development. Biogen’s second tau offering, BIIB076, partnered with Eisai, is expected to yield safety and pharmacokinetic data next year. With aducanumab resurrected, Biogen's Alzheimer’s focus continues.

Selected anti-tau MAbs
Status Project Company Comment, primary completion date
Phase II LY3303560/zagotenemab Lilly Phase II study in early symptomatic Alzheimer's disease, Aug 2021.
  BIIB092/gosuranemab Biogen/Bristol-Myers Squibb Phase II Passport PSP trial failed, phase II Tango trial in AD continues, May 2021.
  RG6100/semorinemab Roche/AC Immune Two phase II trials: prodromal, mild and moderate AD, Jun 2020 and May 2021.
  ABBV-8E12/tilavonemab Abbvie Phase II Arise study in PSP failed in July 2019, two phase II AD trial continue, Apr 2021 and extension study Aug 2026.
Phase I E2814 Eisai Phase I said to be in preparation.
  BIIB076 Biogen/Eisai Healthy volunteers and subjects with AD, Mar 2020.
PSP=progressive supranuclear palsy. Source: EvaluatePharma & clinicaltrials.gov.

Share This Article